Trillium Therapeutics TRIL shares are trading higher on Thursday after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a price target of $16.60 per share.
The stock rose 40% yesterday on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621.
Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.
The company has proprietary medicinal chemistry platform, using fluorine chemistry which permits the creation of new chemical entities with pharmacological properties. The company operates through the single segment being Research and development of therapies for the treatment of cancer.
Trillium Therapeutics shares were trading up 5.22% at $14.30 on Thursday. The stock has a 52-week high of $14.94 and a 52-week low of 24 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
